CHILDRENS CANCER GROUP

儿童癌症组

基本信息

批准号：
2748690
负责人：
GERALD S GILCHRIST
金额：
$ 19.16万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
1981
资助国家：
美国
起止时间：
1981-01-01 至 2002-11-30
项目状态：
已结题

项目摘要

The primary objective of this proposal is to continue to support and expand Mayo Clinic's participation in the activities of Children's Cancer Group through: 1.) Evaluating new cancer chemotherapeutic agents and developing new approaches to treatment of children with cancer by, a) maintaining a leadership role in CCG Phase II and New Agent Study Committees, b) performing pilot studies for potential incorporation into future randomized CCG trials, c) entering patients on new agent studies, d) utilizing the resources in Doctor Ames' pharmacology laboratory to evaluate the pharmacology and pharmacokinetics of cancer chemotherapy. 2.) Improving treatment and potential for cure of various childhood cancers and leukemias by, a) continuing to enter patients into CCG treatment protocols with the expectation that study entries will increase as new studies for various tumor systems are activated, b) playing a leadership role in CCG Strategy Groups in order to develop new approaches to the treatment of childhood cancer, c) participating in the development of new randomized trials for the treatment of specific diseases and maintaining active participation in CCG study committees by Mayo investigators currently assigned to study committees, d) studying long-term effects of treatment. 3.) Studying the biology and epidemiology of childhood cancer by, a) active participation in regional and CCG case-control epidemiology studies, b) making available to CCG the skills and resources of Mayo investigators in Pathology, Immunology, Molecular Biology, cytogenetics and other areas of basic and applied laboratory research. 4.) Improving supportive care of children with cancer by, a) continued participation in CCG supportive care studies, b) standardization of drug administration procedures for various chemotherapeutic agents, c) development and evaluation of methods for controlling cancer- related and procedure-related side-effects. 5.) Providing access for patients in outlying areas to these clinical research programs through affiliates in Des Moines, Iowa; Fargo, North Dakota; Duluth, Minnesota; Regina and Saskatoon, Sasketchewan; Sioux Falls, South Dakota; and Green Bay, Wisconsin. 6.) Active participation in CCG administrative activities by continuing to chair and participate in appropriate committees, including Membership, Data Monitoring, and Constitution and By-Laws.

The primary objective of this proposal is to continue to support and expand Mayo Clinic's participation in the activities of Children's Cancer Group through: 1.) Evaluating new cancer chemotherapeutic agents and developing new approaches to treatment of children with cancer by, a) maintaining a leadership role in CCG Phase II and New Agent Study Committees, b) performing pilot studies for potential incorporation into future randomized CCG trials, c) entering patients on new agent studies, d) utilizing the resources in Doctor AMES的药理学实验室评估癌症化学疗法的药理学和药代动力学。 2.）通过a）继续将患者进入CCG治疗方案，并期望，随着对各种肿瘤系统的新研究的激活，b）在CCG策略组中发挥领导作用，以开发新的方法，从而在ccg策略组中发挥新的方法，从而在ccg策略中发挥了新的治疗方法，从而，研究条目将在ccg策略中发挥新的治疗方法，从而在ccg策略中发挥新的治疗，c在ccg策略中发挥新的治疗，c扮演新的疾病，请参与新的疾病，c扮演新的方法，c扮演新的方法，c参与新的疾病的疾病，c）梅奥研究委员会目前分配给研究委员会的研究委员会，d）研究治疗的长期影响。 3.）研究儿童癌症的生物学和流行病学，a）积极参与区域和CCG病例对照流行病学研究，b）可供CCG提供蛋黄酱研究者在病理学，免疫学，分子生物学，细胞遗传学以及基础和应用实验室研究的其他领域的蛋黄酱研究者的技能和资源。 4.）通过a）继续参与CCG支持性护理研究，b）各种化学治疗剂的药物给药程序的标准化，c）开发和评估控制癌症相关且与程序相关的副作用的方法的开发和评估。 5.）通过爱荷华州得梅因市的分支机构为这些临床研究计划的偏远地区的患者提供访问权限；法戈，北达科他州；明尼苏达州德卢斯；萨斯喀彻温省的里贾纳和萨斯卡通；南达科他州苏福尔斯；和威斯康星州的绿湾。 6.）通过继续主持并参加适当的委员会，包括会员资格，数据监控以及宪法和细则，积极参与CCG行政活动。